According to the Legislative Budget Board (LBB), SB 112 will have no significant fiscal implications for the State of Texas. The bill primarily involves clarifying and extending regulatory applicability to pharmacy benefit managers (PBMs) and health plans that serve Texas residents, even if those plans originate out of state.

The fiscal analysis assumes that any administrative costs related to enforcing the new requirements—such as updating regulations, overseeing compliance, and coordinating inter-state enforcement—can be absorbed within the existing resources of relevant state agencies. This includes agencies such as the Texas Department of Insurance, the Health and Human Services Commission, and the state's public retirement systems.

Additionally, there are no significant fiscal implications anticipated for local governments. The regulatory changes are narrowly focused on state-level insurance oversight and do not impose new mandates or administrative responsibilities on local governmental entities. Therefore, the fiscal impact of SB 1122 is expected to be minimal across all levels of government.

While SB 1122 seeks to address the legitimate concerns surrounding pharmacy benefit manager (PBM) practices and improve transparency for Texas consumers, it does so by expanding state regulatory authority in a manner that may unintentionally intrude into areas governed by federal law—particularly the Employee Retirement Income Security Act of 1974 (ERISA). This raises constitutional and practical concerns about state overreach and exposes Texas to potential litigation over ERISA preemption. The bill’s blanket applicability to all health benefit plans, including self-funded ERISA plans, risks placing undue compliance burdens on employers who operate across multiple states and prefer uniform regulatory standards.

Although the legislative intent is rooted in consumer protection and marketplace fairness, the bill could impose additional costs on businesses and restrict their ability to offer competitive and flexible health plans. Some business advocacy groups have flagged these risks, emphasizing that even well-intentioned PBM reforms must avoid encroaching on federally protected domains. From a limited government perspective, SB 1122, as currently drafted, may exceed the appropriate scope of state regulatory authority.

To reconcile these concerns, an amendment is proposed that would clarify the bill’s applicability only to the extent permitted by federal law. Specifically, the amendment would explicitly exempt ERISA-regulated plans from compliance requirements unless federal courts have upheld state oversight in that context. It would also direct the Texas Department of Insurance to adopt rules aligned with prevailing judicial interpretations, preserving the bill’s consumer protection goals without inviting costly legal conflicts or overstepping constitutional boundaries.

Given the above, Texas Policy Research recommends that lawmakers vote NO unless amended—opposing SB 1122 in its current form while supporting a modified version that respects federal limits and business autonomy while still advancing regulatory transparency for Texas residents.

• Individual Liberty: The bill seeks to protect Texas consumers—particularly patients and local pharmacies—from opaque or predatory practices by pharmacy benefit managers (PBMs), many of whom operate across state lines. By ensuring all Texans receive the same regulatory protections regardless of where their health plan is issued, the bill promotes transparency and predictability in healthcare access. However, the uniform application of state law to all health plans, including ERISA-governed ones, could infringe upon individuals' freedom to select from a broader range of employer-sponsored benefit packages. If ERISA plans become less flexible or more costly due to compliance burdens, consumer choice could ultimately be reduced.
• Personal Responsibility: The bill fosters an environment where consumers can more easily understand and navigate their pharmacy benefits. Requiring consistent rules across plans enhances accountability for both PBMs and patients. It empowers individuals to make better-informed healthcare decisions, promoting a culture of personal responsibility in managing one's own health coverage and costs.
• Free Enterprise: From a free enterprise standpoint, this bill introduces significant regulatory constraints on a segment of the insurance market—particularly self-funded employer plans. It may deter businesses from offering certain health benefits due to the compliance burdens or legal risks introduced by conflicting state and federal regulatory frameworks. The broad reach of the bill could distort competitive dynamics by imposing costs unevenly across the market.
• Private Property Rights: The bill has little direct impact on property rights. However, one could argue that state interference in employer plan design affects the contractual freedom between employers and employees, particularly where ERISA preemption is meant to secure uniformity and predictability across state lines.
• Limited Government: The bill stretches the boundaries of state regulatory power by asserting jurisdiction over out-of-state and federally regulated plans. This potentially conflicts with federal ERISA law and disrupts the traditional balance of federalism. From a limited government perspective, the bill is overly broad and risks placing Texas at odds with constitutional limits on state authority.

• HB 5102 (Same As)